Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @LucieLEllis
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LucieLEllis
-
Lucie Ellis proslijedio/la je Tweet
Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis http://bit.ly/2vSg5l3
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
.
@Novartis have not bought cancer asset this year as economic model showed market potential was not big enough to pay for the deal#nigelsheall head of m&a, to acquire an asset market size must be big enough#LSXWorld@LSXLeadersHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Is a new technology business joining Roivant Sciences' fleet? "VantAI"? Focus to be on image recognition technology for biopharma.
#LSXWorldHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
Due diligence when acquiring assets: 1) focus on studying science; mostly biotech, gene therapy, large molecules, work is now complex, 2nd aspect is environmental; heritage, animal rights, data protection, risks understood 3) work with/trust team
#lsxworld @LSXLeaderspic.twitter.com/FJN4tmKybS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Philippe Loper-Fernandes "there are plenty of ways to engage external experts on due diligence ... must understand what a deal means for the business moving forward"
#LSXWorldHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Lucie Ellis proslijedio/la je Tweet
Pipeline Watch: Phase III Readouts In Atopic Dermatitis, Ischemic Stroke http://bit.ly/2OnhOoR
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
Congratulations
$BIIB. How will you top this latest aducanumab gem? (quote via@statnews )pic.twitter.com/phKXxP9wFu
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Next week I will be hosting a fireside chat with Cedric Ververken, CEO of ConfoTherapeutics, at
#LSXWord Congress on the topic of win/win early-stage biotech partnerships. Any burning questions you have for him? I look forward to an interesting discussion...#biopharmaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
China Coronavirus Cases Up Sharply As Pharma Rushes To Aid http://bit.ly/2S48JlF
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
$NVS#Zolgensma made $390m in 2019, approved midyear in children under 2. It's on a partial trial hold in older patients. I talked to#AveXis President Lennon on the relationship with FDA, the clinical hold and expansion in gene therapyhttps://pink.pharmaintelligence.informa.com/articles/2020/01/28/novartis-avexis-president-lennon-on-rebuilding-trust-with-fda-zolgensma-trial-hold-and-more …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
My
#JPM20 round up is available for free and we don't do that a lot so take advantage. big pharma business strategy, deals, drug pricing and snippets from some of the industry leaders I talked to.https://scrip.pharmaintelligence.informa.com/articles/2020/01/15/a-muted-jp-morgan-but-the-focus-is-execution--and-thats-good-news …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In Vivo's Deals Of The Year contest is now live! https://invivo.pharmaintelligence.informa.com/IV124421/In-Vivos-Top-Alliance-Of-2019-Cast-Your-Vote … Go and pick your winners.
@INVIVOnowHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
Latest installment with all you need to know from
#JPM20#pharma#biotech J.P. Morgan Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And Morehttps://scrip.pharmaintelligence.informa.com/articles/2020/01/15/jp-morgan-day-3-skyrizi-momentum-builds-whats-next-for-amarin-viatris-debuts-and-more …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Lucie Ellis proslijedio/la je Tweet
Vas Narasimhan gets biggest laugh in exchange with
@medicxi 's Francesco De Rubertis who asks 3 CEOs to name their next M&A targets. Vas jokes: I've a question for you: do you feel biotech evaluation expectations have got completely out of hand?!#JPMHC20pic.twitter.com/5uyVIo0udI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
#JPM20 Day 1 round-up from@PharmaScrip team; notably, update on Zolgensma#GeneTherapy reimbursement: no payers to date have used$NVS annuity model, instead preferring outcomes-based payment tied to death or permanent ventilation ($sub)http://bit.ly/3a6ZJocHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lucie Ellis proslijedio/la je Tweet
Interview: KaNDy Menopause Therapy Hits Sweet Spot http://bit.ly/383rHPM
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.